

MindMaze Therapeutics

Organisational simplification supports way forward

MindMaze completed its organisational simplification initiative through several transactions, disposing of most of its remaining non-neurology legacy operations (acquired through its business combination with Relief Therapeutics in Q425). This process has simplified the company's operational structure and should lower its cost base as it focuses on its core neurology business. We believe MindMaze's recently announced US channel partnership with Vibra Healthcare should be a key driver of new customer acquisitions in H226 and we expect updates on this and other collaborations in the coming weeks.

Year end	Revenue (CHFm)	PBT (CHFm)	EPS (CHF)	DPS (CHF)
12/24	0.0	(0.0)	(0.00)	0.00
12/25	0.6	(8.5)	(0.41)	0.00
12/26e	5.9	(6.5)	(0.04)	0.00
12/27e	43.2	26.2	0.14	0.00

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. EPS is fully diluted.

Neuro.io financing completion in H226

The [completion](#) of the organisational simplification process, which is expected to reduce the cost base by about a third, follows the [outlicensing of RLF-OD032](#) and includes an undisclosed cash consideration and the potential for future contingent payments. The first CHF4.0 tranche of the previously announced [CHF8.0m strategic equity fund-raising](#) from [Neuro.ai Group](#) has been completed, resulting in the net issuance of c 17.4m shares. Neuro.io had committed to purchasing a second tranche consisting of an additional CHF4.0m in mandatory convertible loan notes, and while guidance was for this to have been completed in mid-2026, MindMaze now expects this to be funded in two instalments in September and November 2026. The company reiterated that the economic terms of the remaining investment are unchanged. We note that both parties continue to explore potential strategic opportunities between the companies.

Recruitment underway in key European trials

The first patients using MindMaze's high-dose, high-intensity rehabilitation platform [have been enrolled](#) in the flagship [SwissNeuroRehab study](#). This initiative involving six major Swiss centres is designed to generate clinical and economic data from the involvement of novel digital therapeutics platforms such as those offered by MindMaze, in conditions such as stroke and traumatic brain injury (TBI). MindMaze recently also started the [REACT-AVC study](#) at Hospices Civils de Lyon, which is assessing the company's MindMotion GO home-based rehabilitation platform for early outpatient and home-based stroke rehabilitation. We expect data from these two studies to support reimbursement protocols in Europe, mirroring the at-home CPT reimbursement code model in the US.

MindMaze's is due to announce H126 financial results in the coming weeks; we expect updates on key commercial initiatives, including the Vibra US channel partnership and the [recent appointment of Professor John W Krakauer](#) (the original designer of MindPod) as a strategic advisor to support the company's next growth phase in the US market.

Organisational and clinical trial update


Pharma and biotech

18 August 2026

Price CHF0.23
Market cap CHF42m

Net cash at 31 December 2025 CHF9.5m
Shares in issue 181.5m
Free float 45.0%
Code MMTX
Primary exchange SWX
Secondary exchange N/A

Share price performance



Business description

MindMaze Therapeutics is a Swiss med-tech company delivering clinical interventions through neurotherapeutics to treat neurological disorders (such as stroke, TBI and Parkinson's disease), integrating software-based treatments with innovative technology, data and AI to improve patient outcomes.

Analysts

Jyoti Prakash, CFA +44 (0)20 3077 5700
Pooya Hemami, OD +44 (0)20 3077 5700
MBA, CFA

healthcare@edisongroup.com
[Edison profile page](#)

**MindMaze Therapeutics is
a research client of Edison
Investment Research Limited**

General disclaimer and copyright

This report has been commissioned by MindMaze Therapeutics and prepared and issued by Edison, in consideration of a fee payable by MindMaze Therapeutics. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.